Antianxiety effect of cannabidiol in the elevated plus-maze
FS Guimarães, TM Chiaretti, FG Graeff, AW Zuardi - Psychopharmacology, 1990 - Springer
FS Guimarães, TM Chiaretti, FG Graeff, AW Zuardi
Psychopharmacology, 1990•SpringerIn order to assess the presence of anxiolytic properties in cannabidiol (CBD) the drug was
tested in an elevated plus-maze model of anxiety, in rats. Doses of 2.5, 5.0 and 10.0 mg/kg
significantly increased the entry ratio (open/total number of entries), an anxiolytic-like effect.
CBD at a dose of 20.0 mg/kg was no longer effective. None of the doses of CBD used
changed total number of entries, a measure of total exploratory activity. Diazepam (2.0
mg/kg) also caused an anxiolytic-like effect in this model. These results indicate that CBD …
tested in an elevated plus-maze model of anxiety, in rats. Doses of 2.5, 5.0 and 10.0 mg/kg
significantly increased the entry ratio (open/total number of entries), an anxiolytic-like effect.
CBD at a dose of 20.0 mg/kg was no longer effective. None of the doses of CBD used
changed total number of entries, a measure of total exploratory activity. Diazepam (2.0
mg/kg) also caused an anxiolytic-like effect in this model. These results indicate that CBD …
Abstract
In order to assess the presence of anxiolytic properties in cannabidiol (CBD) the drug was tested in an elevated plus-maze model of anxiety, in rats. Doses of 2.5, 5.0 and 10.0 mg/kg significantly increased the entry ratio (open/total number of entries), an anxiolytic-like effect. CBD at a dose of 20.0 mg/kg was no longer effective. None of the doses of CBD used changed total number of entries, a measure of total exploratory activity. Diazepam (2.0 mg/kg) also caused an anxiolytic-like effect in this model. These results indicate that CBD causes a selective anxiolytic effect in the elevated plusmaze, within a limited range of doses.
Springer